^
Association details:
| Biomarker: | EGFR exon 19 mutation |
|---|---|
| Cancer: | Small Cell Lung Cancer |
| Drug: | Tagrisso (osimertinib) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Clinical and genetic characteristics of EGFR-mutant lung adenocarcinoma transformed SCLC.
Published date:
05/19/2021
Excerpt:
...60-year-old woman in our transformed SCLC cohort harbored EGFR 19 del mutant at allele frequency of 50.39%，she received osimertinib plus epirubicin/cyclophosphamide as 1st line treatment and reached partial response, with survival of 4 years to date....SCLC patients with EGFR mutation who transformed from lung adenocarcinoma may be potential benefit population using EGFR inhibitors.
Secondary therapy:
cyclophosphamide + epirubicin
DOI:
10.1200/JCO.2021.39.15_suppl.e20588
